Say Hello!
Don’t be shy.

 
0333 323 1843
 

[email protected]

 

BioCity Group HQ:
Pennyfoot Street
Nottingham
NG1 1GF

BiVictriX Therapeutics

BiVictriX Therapeutics

Home > Companies > BiVictriX Therapeutics

Established in 2016, BiVictriX Therapeutics Ltd is a North-West based biotech focused on developing and licensing novel, highly-selective, bispecific Antibody Drug Conjugates (ADCs) to target unmet medical need in blood cancer.

 

ADCs, which were originally coined as the new ‘Magic Bullet’ therapeutics in the field of oncology, are currently limited by their lack of target specificity. BiVictriX has invented a novel targeting strategy, the ‘Dual Targeting Approach’, to improve ADC specificity towards malignant cells through targeting two cell surface antigens simultaneously, expressed solely in a tumour-restricted co-expression pattern.

 

The Company has recently secured seed funding to commence operations and perform early Proof Of Concept studies on BiVictriX’s Lead Candidate, a dual targeting ADC targeting Acute Myeloid Leukemia (AML).

 

Established in 2016, BiVictriX Therapeutics Ltd is a North-West based biotech focused on developing and licensing novel, highly-selective, bispecific Antibody Drug Conjugates (ADCs) to target unmet medical need in blood cancer.

ADCs, which were originally coined as the new ‘Magic Bullet’ therapeutics in the field of oncology, are currently limited by their lack of target specificity. BiVictriX has invented a novel targeting strategy, the ‘Dual Targeting Approach’, to improve ADC specificity towards malignant cells through targeting two cell surface antigens simultaneously, expressed solely in a tumour-restricted co-expression pattern.

The Company has recently secured seed funding to commence operations and perform early Proof Of Concept studies on BiVictriX’s Lead Candidate, a dual targeting ADC targeting Acute Myeloid Leukemia (AML).